The S-3 enables immediate resale by three Chinese individual holders (Fengjun Xue, Xiangdie Liu, Xiangyang Xu) who hold the convertible notes and warrants. Monitor for selling pressure as the registration becomes effective — the 4.99% beneficial ownership cap on each holder limits block sales but does not prevent continuous dribble-out. The company's NYSE American listing is conditional on a compliance plan through Nov 2027; any equity issuance that triggers the 19.99% exchange cap requires stockholder approval.
Price Chart
Executive Summary
Picard Medical filed an S-3 shelf registration to register up to 500,000 shares of common stock for resale by three selling stockholders. These shares are issuable upon conversion of $1.0M in convertible notes issued on September 30, 2026, and exercise of associated pre-funded warrants. The company receives no proceeds from resales, but the registration enables near-term overhang of up to 20.3% dilution relative to the 2,458,574 shares outstanding.
Key Financial Metrics
Key Facts
- S-3 registers 500,000 shares for resale: 250,000 upon conversion of $1.0M convertible notes (3% interest, maturity Sept 2027) and 250,000 upon exercise of pre-funded warrants at $0.0001/share.
- Conversion price floored at $4.00/share; at current market (avg ~$10.85 on Oct 12, 2026), full conversion yields 250,000 shares plus 250,000 warrant shares.
- Company receives no proceeds from resales; only nominal $0.0001/share from warrant exercises.
- Pro forma shares outstanding would increase from 2,458,574 to 2,958,574 — dilution of ~20.3% if all shares issued and sold.
- NYSE American non-compliance notice received May 2026 for stockholders' equity of $3.8M; compliance plan accepted through Nov 2027.
- Auditor's report includes going-concern explanatory paragraph (MaloneBailey, LLP).
- Securities class action pending (Louie v. Picard Medical) — motion to dismiss filed Sept 2026, hearing set Feb 2027.
Financial Impact
Up to 500,000 shares registered for resale; at $10.85/share (Oct 12 avg), potential market overhang of ~$5.4M. Dilution of ~20.3% on 2.46M shares outstanding.
Risk Factors
- Potential 20.3% dilution from full conversion and warrant exercise.
- Resale overhang may depress stock price; three holders with Chinese addresses may have different selling urgency.
- NYSE American continued listing requires meeting stockholders' equity milestones by Nov 2027.
- Securities class action (motion to dismiss pending) adds legal cost and uncertainty.
- Going-concern opinion from auditor indicates capital adequacy risk.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001437749-26-033230 |
| Exhibit: ex_1026466.htm | 0001437749-26-033230 |
| Exhibit: ex_1026465.htm | 0001437749-26-033230 |
| Exhibit: ex_1028549.htm | 0001437749-26-033230 |
| Document: 0001437749-26-033230-index-headers.html | 0001437749-26-033230 |
| Document: 0001437749-26-033230-index.html | 0001437749-26-033230 |
| Document: 0001437749-26-033230.txt | 0001437749-26-033230 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $7.09 | awaiting T+60 | — | $6.85 (−3.39%) |
Oct 22, 2026 4d ago | S-3 | $7.37 | awaiting T+60 | — | $6.85 (+7.06%) |
Oct 6, 2026 20d ago | 8-K | $8.74 | awaiting T+60 | — | $6.85 (+21.62%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.85 (+7701.82%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.85 (+4181.25%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.85 (+4466.67%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.85 (+3943.68%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.85 (+4293.84%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.85 (−49.26%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.85 (+49.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers